# CheckMate901 (NCT03036098)

> Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03036098
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Bristol-Myers Squibb
- Conditions: Urothelial Cancer
- Interventions: Nivolumab; Ipilimumab; Gemcitabine; Cisplatin; Carboplatin
- Enrollment: 1314
- Primary outcome: Overall Survival (OS) in Cisplatin-ineligible Randomized Participants for Primary Study
- Primary outcome: Overall Survival (OS) in Programmed Death-Ligand 1 (PD-L1) Positive (≥ 1%) Randomized Participants by Immunohistochemistry (IHC) for Primary Study
- Primary outcome: Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) [Using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1] in Cisplatin-eligible Participants for Sub-study
- Primary outcome: Overall Survival (OS) in Cisplatin-eligible Participants for Sub-study

## Commentary we found

- X threads: 128
- YouTube: 82
- Podcasts: 82
- X videos: 5

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=checkmate901-nct03036098

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03036098", "email": "<work email>"}; the inbox owner confirms by the emailed link.